[Myelotoxicity of epirubicin].
Epirubicin (pharmorubicin, India), an antitumor antibiotic of the anthracycline group, was studied in regard to its effect on peripheral blood, bone marrow and lymphoid organs (the thymus and spleen) of CBA mice after its intraperitoneal administration in a single dose equal to the MIC (7.8 mg/kg) and in a course dose (1/5 of the MIC 5 times a day). The cytogenetic impairments induced by the cytostatic were estimated on metaphase plates with the bone marrow specimens and by counting the peripheral blood erythrocytes with micronuclei (the micronuclear test). It was shown that epirubicin induced cytogenetic disturbances in the hemopoietic cells within the first 72 hours. The antibiotic had a marked reversible effect on the erythroid population and lymphoid tissues and a moderate toxic action on the granulocyte population. The antibiotic did not affect thrombocytopoiesis. The single administrations had a more pronounced and prolonged myelotoxic and lymphotropic effect.
Gol'dberg
E D
ED
Karpova
G V
GV
Kolmogorova
L A
LA
Voronova
O L
OL
Fomina
T I
TI
Andreeva
E A
EA
D000818:Animals; D001769:Blood / Q000187:drug effects*; D001853:Bone Marrow / Q000187:drug effects*; D015251:Epirubicin / Q000633:toxicity*; D005260:Female; D008221:Lymphoid Tissue / Q000187:drug effects*; D051379:Mice; D008808:Mice, Inbred CBA; D008826:Microbial Sensitivity Tests
D015251:Epirubicin
O mielotoksichnosti épirubitsina.